PTGS2 and metabolic dysfunction-associated steatotic liver disease: Our results demonstrated that α-lack-SPI administration significantly reduced hepatic COX-2 protein expression in HFD-fed rats, and its beneficial effects on MASLD may also be partly attributed to its COX-2 targeting inhibitory effects.